A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma

Trial Profile

A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms ImmunoCobiVem
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 14 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top